IBDEI0AM ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4750,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,4750,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,4751,0)
 ;;=E11.349^^24^305^81
 ;;^UTILITY(U,$J,358.3,4751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4751,1,3,0)
 ;;=3^Diabetes Type 2 w/ Severe Nonprlf Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,4751,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,4751,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,4752,0)
 ;;=E11.351^^24^305^78
 ;;^UTILITY(U,$J,358.3,4752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4752,1,3,0)
 ;;=3^Diabetes Type 2 w/ Prolif Diab Rtnop w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,4752,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,4752,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,4753,0)
 ;;=E11.359^^24^305^79
 ;;^UTILITY(U,$J,358.3,4753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4753,1,3,0)
 ;;=3^Diabetes Type 2 w/ Prolif Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,4753,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,4753,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,4754,0)
 ;;=E11.610^^24^305^58
 ;;^UTILITY(U,$J,358.3,4754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4754,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diab Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,4754,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,4754,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,4755,0)
 ;;=E11.618^^24^305^55
 ;;^UTILITY(U,$J,358.3,4755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4755,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diab Arthropathy
 ;;^UTILITY(U,$J,358.3,4755,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,4755,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,4756,0)
 ;;=E11.620^^24^305^56
 ;;^UTILITY(U,$J,358.3,4756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4756,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,4756,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,4756,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,4757,0)
 ;;=E11.621^^24^305^67
 ;;^UTILITY(U,$J,358.3,4757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4757,1,3,0)
 ;;=3^Diabetes Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,4757,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,4757,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,4758,0)
 ;;=E11.622^^24^305^83
 ;;^UTILITY(U,$J,358.3,4758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4758,1,3,0)
 ;;=3^Diabetes Type 2 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,4758,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,4758,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,4759,0)
 ;;=E11.628^^24^305^82
 ;;^UTILITY(U,$J,358.3,4759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4759,1,3,0)
 ;;=3^Diabetes Type 2 w/ Skin Complications
 ;;^UTILITY(U,$J,358.3,4759,1,4,0)
 ;;=4^E11.628
 ;;^UTILITY(U,$J,358.3,4759,2)
 ;;=^5002658
 ;;^UTILITY(U,$J,358.3,4760,0)
 ;;=E11.630^^24^305^77
 ;;^UTILITY(U,$J,358.3,4760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4760,1,3,0)
 ;;=3^Diabetes Type 2 w/ Periodontal Disease
 ;;^UTILITY(U,$J,358.3,4760,1,4,0)
 ;;=4^E11.630
 ;;^UTILITY(U,$J,358.3,4760,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,4761,0)
 ;;=E11.638^^24^305^76
 ;;^UTILITY(U,$J,358.3,4761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4761,1,3,0)
 ;;=3^Diabetes Type 2 w/ Oral Complications
 ;;^UTILITY(U,$J,358.3,4761,1,4,0)
 ;;=4^E11.638
 ;;^UTILITY(U,$J,358.3,4761,2)
 ;;=^5002660
 ;;^UTILITY(U,$J,358.3,4762,0)
 ;;=E11.69^^24^305^84
 ;;^UTILITY(U,$J,358.3,4762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4762,1,3,0)
 ;;=3^Diabetes Type 2 w/ Spec Complication NEC
 ;;^UTILITY(U,$J,358.3,4762,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,4762,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,4763,0)
 ;;=E11.8^^24^305^85
 ;;^UTILITY(U,$J,358.3,4763,1,0)
 ;;=^358.31IA^4^2
